ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
Dow Jones
38.675,68
1,18%
Euro vs US Dollar
1,07735
0,00%
Bitcoin
62.959,61
0,11%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NYSE
  6. Abbott Laboratories (ABT)

  7. Abbott Laboratories (ABT) News

ABT

Abbott Laboratories (ABT)

Abbott Laboratories
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NYSE:ABT
DatumZeitQuelleÜberschriftSymbolFirma
29/04/202415h00PR Newswire (US)Abbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the KneeNYSE:ABTAbbott Laboratories
17/04/202417h37IH Market NewsAbbott Laboratories Reports Strong Q1 Sales Growth Amid Earnings Decline, Raises Full-Year GuidanceNYSE:ABTAbbott Laboratories
17/04/202413h30PR Newswire (US)Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance RangesNYSE:ABTAbbott Laboratories
17/04/202412h59IH Market NewsUS Index Futures See Gains, Oil Prices DipNYSE:ABTAbbott Laboratories
03/04/202413h12IH Market NewsCal-Maine Surges on Strong Quarterly Performance, Taiwan Earthquake Disrupts Tech Supply Chain, and MoreNYSE:ABTAbbott Laboratories
02/04/202415h00PR Newswire (US)Abbott Receives FDA Approval for TriClip™, First-of-Its-Kind Device to Repair Leaky Tricuspid Heart ValveNYSE:ABTAbbott Laboratories
01/04/202415h00PR Newswire (US)Abbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient's BedsideNYSE:ABTAbbott Laboratories
27/03/202421h30PR Newswire (US)Abbott Hosts Conference Call for First-Quarter EarningsNYSE:ABTAbbott Laboratories
19/03/202413h00PR Newswire (Canada)Une première au Canada -- Abbott fait progresser le traitement de la douleur chronique grâce au plus petit système de stimulation de la moelle épinière implantée et rechargeable au mondeNYSE:ABTAbbott Laboratories
19/03/202413h00PR Newswire (Canada)Canadian First - Abbott Advances Chronic Pain Management with the World's Smallest Implanted, Rechargeable Spinal Cord Stimulation SystemNYSE:ABTAbbott Laboratories
06/03/202415h00PR Newswire (US)Real-World Data Show Abbott's FreeStyle Libre® Systems and GLP-1 Medicines Work Better Together for People with Type 2 DiabetesNYSE:ABTAbbott Laboratories
05/03/202401h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABTAbbott Laboratories
05/03/202401h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABTAbbott Laboratories
05/03/202401h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABTAbbott Laboratories
05/03/202401h09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABTAbbott Laboratories
05/03/202401h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABTAbbott Laboratories
05/03/202401h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABTAbbott Laboratories
05/03/202400h56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABTAbbott Laboratories
05/03/202400h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABTAbbott Laboratories
05/03/202400h44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABTAbbott Laboratories
05/03/202400h39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABTAbbott Laboratories
01/03/202423h53Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:ABTAbbott Laboratories
01/03/202423h45Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:ABTAbbott Laboratories
01/03/202423h39Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:ABTAbbott Laboratories
01/03/202423h32Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:ABTAbbott Laboratories
01/03/202423h25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:ABTAbbott Laboratories
01/03/202423h22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:ABTAbbott Laboratories
28/02/202400h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABTAbbott Laboratories
23/02/202423h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABTAbbott Laboratories
23/02/202423h43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABTAbbott Laboratories
 Showing the most relevant articles for your search:NYSE:ABT

Kürzlich von Ihnen besucht

TG
CBK
Commerzbank
TG
LHA
Deutsche Lufthansa
COIN
BTCUSD
Bitcoin
PM
XAUUSD
Gold vs US Dollar
TG
BAYN
Bayer
USOTC
BNPQY
BNP Paribas (QX)
NASDAQ
QQQ
Invesco QQQ Trust Series 1
FX
EURGBP
Euro vs Sterling
USOTC
RHHBY
Roche (QX)
DBI
TDXP
Tec DAX
NASDAQ
AMZN
Amazon.com
FX
EURJPY
Euro vs Yen
TG
BAS
BASF
NYSE
XOM
Exxon Mobil
CCOM
US100
US Tech 100
NYSE
NKE
Nike
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten